STIPLEX
LIVE

Serial Number

98326981

Owner

SpeeDx Pty Ltd

Attorney

Sydney R. Jensen

Filing Date

Dec 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

STIPLEX Trademark

Serial Number: 98326981

STIPLEX is a trademark filed by SpeeDx Pty Ltd on December 21, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

SpeeDx Pty Ltd (21 trademarks)

Suite G16, National Innovation Centre,

Entity Type: 82

Trademark Details

Filing Date

December 21, 2023

Registration Date

Not Registered

Published for Opposition

August 12, 2025

Goods & Services

Pharmaceutical and veterinary preparations and substances consisting of catalytic DNA molecules being diagnostic reagents and preparations, except for medical or veterinary use for the purpose of detection and identification of pathogens, for the detection of antibiotic resistance, and medical diagnostic reagents for the analysis of body fluids specifically for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, and for analysis of response to therapy and preparations for detecting and preparations for analysis of gene expression specifically for medical or medical research purposes; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing preparations being nucleic acid sequences for medical use; chemical preparations containing enzymes for medical purposes specifically for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes specifically for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; enzymes for pharmaceutical, veterinary and medical purposes specifically for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; medical kits containing medical diagnostic reagents for testing and analysis of bodily fluids for use in disease detection and/or analysis of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping; clinical diagnostic preparations for medical or veterinary use, namely, diagnostic preparations for medical or veterinary use; biological chemical diagnostic test kits in the nature of medical diagnostic reagents and assays for testing body fluids for the presence of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders; biological chemical test kits containing diagnostic preparations for medical purposes used in medical laboratories in the nature of nucleic acid substrates used for analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders

Reagents for scientific or medical research use; enzymes for industrial or scientific purposes; nucleic acid for other than medical and veterinary purposes; nucleic recombinant acid for other than medical and veterinary purposes; acids namely inorganic acids for industrial purposes; DNA polymerase for scientific purposes; chemicals used in environmental monitoring in the nature of chemical preparations for scientific purposes, other than for medical or veterinary use;

Medical services; human healthcare services; medical testing services relating to the diagnosis and treatment of disease; genetic testing for medical purposes; medical and health care services specifically dna, genetics and genetic testing for medical purposes; medical diagnostic services in the nature of medical testing and medical analysis services for diagnostic purposes provided by medical laboratories; medical diagnostic imaging and molecular medicine being medical services; molecular medical diagnostics testing;

Surgical apparatus and instruments; medical instrument for diagnostic use, namely, apparatus for medical diagnostic testing to diagnose and identify pathogens, infections, and infectious diseases, or other tissue-based diagnostic testing, cytology and cell-based testing specifically for the purposes of analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; medical diagnostic apparatus for diagnosis and identification of, infections, and infectious diseases; diagnostic testing kits consisting primarily of medical diagnostic apparatus and instruments for use in disease detection, namely to diagnose and identify pathogens, infections, and infectious diseases by way of detecting antibiotic resistance, analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and analysis of response to therapy; point of care medical devices, namely, medical apparatus for testing for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy for treatment of infectious diseases, immunological diseases and autoimmune diseases; medical screening kits comprised of medical screening and testing apparatus for the diagnosis of disease, detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired and inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy

Scientific and technological services and research and design relating thereto, namely, DNA analysis services for scientific research purposes, scientific research consulting in the field of genetics; scientific research in the field of genetics; genetic engineering services for scientific purposes; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; research relating to chemistry; scientific research relating to chemistry; research in the field of chemistry; product development of medical diagnostic apparatus; design of medical diagnostic apparatus; research relating to molecular sciences; biological, bacteriological, chemical, biochemical, dna, rna, protein, polynucleic acid and molecular analysis and evaluation services to diagnose and identify pathogens, infections, and infectious diseases for medical or scientific research purposes; dna and rna and polynucleic acid and protein sequencing, analysis and evaluation services for scientific purposes; genome sequencing services and the analysis and evaluation of data resulting therefrom in the nature of genetic testing for scientific research purposes; scientific research namely provision of reports relating to scientific and medical experiments, the results of scientific and medical experiments and tests, the analysis and evaluation of scientific and medical data, and data generated by scientific and medical experiments and tests; scientific and medical research and development services in the field of the diagnosis of disease, detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; custom design and development of biochemical assays;

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 7, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 12, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 12, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 6, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 7, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 7, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 7, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 7, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 7, 2025 CNEA
ASSIGNED TO EXAMINER
Jun 5, 2025 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 31, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 30, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 30, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 30, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 30, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 30, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 22, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 8, 2024 NWOS
NEW APPLICATION ENTERED
Dec 21, 2023 NWAP